1779PImpact of timing and technique of gastrostomy placement on the outcome of patients (pts) with head and neck cancer (HNC) von Lostes Bardaji, M J, Diaz, N M, Hernando, A, Puiggrós, C, Vilacampa, G, Assaf, J D, Saudi, N, Ros, J, Garcia, A, Bescós-Atin, C, Lorente, J, Giralt, J, Viaplana, C, Biosca, M, Tabernero, J, Felip, E, Dienstmann, R, Brana, I

Volltext

50P Transcriptomic profiles of CD32b in breast cancer predict outcome and are associated with immune activation von Rojas Laimito, K.I., Vieito Villar, M., Galvao de Aguiar, V., Saavedra Santa Gadea, O., Lostes Bardaji, M.J., Oberoi, A., Alonso, G., Brana, I., Tabernero, J., Garralda, E.

Volltext

223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1)... von Toledo, R.D.A., García, A.M. Calahorro, Moreno, A.B., Mirallas, O., Galvao, V., Casal, G. Alonso, Vieito, M., Braña, I., Oberoi, A., Bardaji, M.J. Lostes, Keough, K.C., Navarro, F., Jimenez, J., Olano, A. Mel, Nuciforo, P.G., Abbott, C., Pugh, J.L., Chen, R., Boyle, S., Garralda, E.

Volltext

294P Adult population with BRAF-mutated (BRAFmut) and NF1-mutated (NF1mut) gliomas. Analysis of the potential role of targeted therapy (TT) in these patients (pts) von Lostes Bardaji, M.J., Rezqallah Aron, M.A., Gonzalez Rodriguez, M., Villacampa Javierre, G., Martinez Saez, E., Auger, C., Maldonado, X., Martinez Ricarte, F., Tabernero, J., Carles Galceran, J., Garralda, E., Vieito Villar, M.

Volltext

1080TiP An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in... von Galvao, V., Palomero, J., Creus-Gonzalez, I., Lostes Bardaji, M.J., Lozano-Rabella, M., Garcia-Garijo, A., Yuste, A., Rodriguez, L., Villalobos Alberú, X., Rotxes, M., Vieito Villar, M., Saavedra Santa Gadea, O., Alonso, G., Braña, I., Muñoz-Couselo, E., Querol, S., Tabernero, J., Martín-Lluesma, S., Gros, A., Garralda, E.

Volltext

702P Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy von Rojas Laimito, K.I., Vieito Villar, M., Moya Hernández, M.Á., Pretelli, G., Lostes Bardaji, M.J., Saavedra Santa Gadea, O., Hernando Calvo, A., Galvao, V., Oberoi, A., Alonso, G., Braña, I., Ginard Moya, J., Baraibar Argota, I., Saura Manich, C., Muñoz Couselo, E., Macarulla, T., Garcia Duran, C., Carles Galceran, J., Tabernero, J., Garralda, E.

Volltext

538P Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials von Pretelli, G., Laimito, K.I. Rojas, Alonso, G., Bardaji, M.J. Lostes, Calvo, A. Hernando, Galvao, V., Oberoi, A., Morillo, B. Ortega, Santa Gadea, O. Saavedra, Moya, J. Ginard, Manich, C. Saura, Fernandez, M.E. Elez, Ortiz, C., Couselo, E. Muñoz, Braña, I., Perez, A. Callejo, Galceran, J. Carles, Felip, E., Garralda, E., Villar, M. Vieito

Volltext

702P Genomic alterations in epigenetic modifiers and response to epigenetic-targeted agents (ETAs) in patients (pts) with recurrent/metastatic (R/M) salivary gland tumours (SGTs) von Rezqallah Aron, M.A., Hernando-Calvo, A., Galvao de Aguiar, V., Saavedra Santa Gadea, O., Assaf Pastrana, J.D., Lostes Bardaji, M.J., Rojas Laimito, K.I., Aguilar Izquierdo, S., Berché, R., Tian, T., Bescós, C., Lorente, J., Giralt, J., Temprana-Salvador, J., Alberola, M., Dienstmann, R., Felip, E., Garralda, E., Vieito Villar, M., Brana, I.

Volltext

729MO Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory... von Melero, I., De Miguel, M.J., Alonso Casal, G., Goebeler, M-E., Ramelyte, E., Calvo, E., Garralda, E., Dummer, R., Rodríguez-Ruiz, M.E., Sayehli, C.M., Sanmamed, M.F., Ramón, J.L., Lostes Bardaji, M.J., Gromke, T., Schuler, M.H.H., Fettes, P., Klar, K., Schuberth-Wagner, C., Wischhusen, J., Leo, E.

Volltext

374P Temozolamide (TMZ) rechallenge at standard or metronomic dose versus other treatments in patients (pts) with high grade glioma with TMZ free-interval (TFI) longer than 3 month... von Garcia-Alvarez, A., Saoudi, N., Gonzalez, M., Ruiz-Pace, F., Saez, E. Martinez, Bardaji, M.J. Lostes, Pastrana, J.D.D. Assaf, Martinez-Ricarte, F., Maldonado, X., Dienstmann, R., Carles, J., Villar, M. Vieito

Volltext

1623P Phase I clinical trials (CT) forge on despite COVID-19 von Bardaji, M.J. Lostes, Aliende, E., Moreno, M., Oberoi, H.K., Braña, I., Saavedra, O., Villar, M. Vieito, Alonso, G., Galvao, V., Carballo, N., Beltran, M., Rovira, P., Cidoncha, I., Manich, C. Saura, Mercade, T. Macarulla, Oaknin, A., Galceran, J. Carles, Felip, E., Garralda, E., Pujol, S. Perez

Volltext

1779P - Impact of timing and technique of gastrostomy placement on the outcome of patients (pts) with head and neck cancer (HNC) von Lostes Bardaji, M.J., Diaz, N.M., Hernando, A., Puiggrós, C., Vilacampa, G., Assaf, J.D., Saudi, N., Ros, J., Garcia, A., Bescós-Atin, C., Lorente, J., Giralt, J., Viaplana, C., Biosca, M., Tabernero, J., Felip, E., Dienstmann, R., Brana, I.

Volltext

Impact of timing and technique of gastrostomy placement on the outcome of patients (pts) with head and neck cancer (HNC) von Lostes Bardaji, M.J., Diaz, N.M., Hernando, A., Puiggrós, C., Vilacampa, G., Assaf, J.D., Saudi, N., Ros, J., Garcia, A., Bescós-Atin, C., Lorente, J., Giralt, J., Viaplana, C., Biosca, M., Tabernero, J., Felip, E., Dienstmann, R., Brana, I.

Volltext

77P Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy von Vieito Villar, M., Rojas Laimito, K.I., López, D., Berché, R., Saavedra Santa Gadea, O., Alonso Casal, G., Galvao de Aguiar, V., Lostes Bardaji, M.J., Braña, I., Tabernero, J., Garralda Cabanas, E.

Volltext

93P Evolving landscape of targeted therapies (TT) in early phase clinical trials (EPCT): The RESISTANCE project (360R) von Rossi, A., Braña, I., Villar, M. Vieito, Casal, G. Alonso, Santa Gadea, O. Saavedra, Mirallas, O., Bardaji, M.J. Lostes, Galvao, V., Laimito, K.I. Rojas, Oberoi, A., Pretelli, G., Morillo, B. Ortega, Sanz, M., Izquierdo, S. Aguilar, Raskina, K., Dienstmann, R., Vivancos, A., Tabernero, J., Garralda, E., Calvo, A. Hernando

Volltext

29O Clinical characterization of long-term survivors in phase I clinical trials von Mirallas, O., Rossi, A., Fernández, E.M., Garcia-Galea, E., Cano, K.S. Vega, Moya, J. Ginard, Calvo, A. Hernando, Pretelli, G., Bardaji, M.J. Lostes, Oberoi, A., Galvao, V., Laimito, K.I. Rojas, Morillo, B. Ortega, Casal, G. Alonso, Izquierdo, S. Aguilar, Braña, I., Dienstmann, R., Villar, M. Vieito, Garralda, E.

Volltext

51P Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit von Rojas Laimito, K.I., Vieito Villar, M., Fullana Grimalt, B., Berché, R., Hierro Carbo, C., Saavedra Santa Gadea, O., Braña, I., Alonso Casal, G., Galvao de Aguiar, V., Lostes Bardaji, M.J., Oliveira, M., Verdaguer, H., Morales Barrera, R., Garcia Duran, C., Zamora, E., Carles Galceran, J., Macarulla, T., Tabernero, J., Garralda Cabanas, E.

Volltext